CDA | Evidence Driven
CDA | Evidence Driven

bimekizumab

Details

Generic Name:
bimekizumab
Project Status:
Pending
Therapeutic Area:
Hidradenitis suppurative
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0856-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderate-to-severe hidradenitis suppurativa who have inadequate response to conventional systemic therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Bimzelx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 6, 2024